Cancer-related Molecular Pathways Open access Peer reviewed

Detection of DHRS2-associated E3 Ubiquitin Ligases in Breast Cancer Cell Lines

Neslihan Abacı, Damla Şakar, Burcu Salman Yaylaz, Seyma Punar

Experimed | Aug 12, 2026

Scollr summary

What this paper is about

Differential patterns across cell types indicate DHRS2 as a context-dependent modulator of ubiquitin-mediated pathways, supporting its relevance in biomarker discovery and therapeutic targeting in breast cancer.

Full abstract

Read the full abstract

Objective: The ubiquitin system plays a central role in regulating intracellular protein homeostasis and cellular signaling. E3 ubiquitin ligases, in particular, are key modulators of protein degradation and have been implicated in cancer progression, including breast cancer. DHRS2, a gene known to suppress MDM2 activity through its ubiquitin-binding domain, has recently emerged as a potential regulator in tumor biology. This study investigated how DHRS2 expression influences selected E3 ubiquitin ligase genes in breast epithelial cells.Materials and Methods: MCF-7 and MCF-10A cell lines were used. DHRS2 was either overexpressed using a vector-based system, or silenced via siRNA. After transfection, quantitative reverse transcription polymerase chain reaction (qRT–PCR) was performed to evaluate changes in the expression levels of BRCA1, BARD1, and STUB1.Results: In MCF-7 cells, DHRS2 overexpression induced a fourfold increase in BRCA1 expression, whereas STUB1 and BARD1 were downregulated (0.56-fold). In MCF-10A cells with naturally low DHRS2, STUB1 expression increased 1.5-fold after DHRS2 knockdown, and BARD1 expression correlated positively with DHRS2 levels.Conclusion: This study highlights a potential regulatory link between DHRS2 and key E3 ubiquitin ligases-BRCA1, BARD1, and STUB1. Differential patterns across cell types indicate DHRS2 as a context-dependent modulator of ubiquitin-mediated pathways, supporting its relevance in biomarker discovery and therapeutic targeting in breast cancer.

Direct answer

What can I do from this paper page?

Use this page to scan "Detection of DHRS2-associated E3 Ubiquitin Ligases in Breast Cancer Cell Lines" quickly: start with the summary and abstract, then check the authors, source, topics, and related papers. From here, open Scollr to follow Cancer-related Molecular Pathways research, save the paper, or map adjacent work.

Authors

Researchers on this paper

Neslihan Abacı

first | Istanbul University | ORCID 0000-0002-9962-4010

Damla Şakar

middle | Istanbul University

Burcu Salman Yaylaz

middle | Istanbul University | ORCID 0000-0002-9144-3899

Seyma Punar

last | Istanbul University | ORCID 0000-0002-7722-7401

Research areas

Follow related topics

Citation

BibTeX

@article{Abac2026Detection,
  title = {Detection of DHRS2-associated E3 Ubiquitin Ligases in Breast Cancer Cell Lines},
  author = {Neslihan Abacı and Damla Şakar and Burcu Salman Yaylaz and Seyma Punar},
  journal = {Experimed},
  year = {2026},
  doi = {10.26650/experimed.1789751},
  url = {https://doi.org/10.26650/experimed.1789751}
}

FAQ

Using this paper in a discovery workflow

How do I find related work for this paper?

Use the related papers and topic links on this page as starting points. In Scollr, you can also open the paper and build a literature map around its references, citing papers, and related work.

How can I keep up with new Cancer-related Molecular Pathways research papers?

Follow Cancer-related Molecular Pathways research in Scollr. New papers from the topic flow into a personalized feed, and you can save useful studies to revisit later.

Can I cite this paper from this page?

This page includes a static BibTeX block for Detection of DHRS2-associated E3 Ubiquitin Ligases in Breast Cancer Cell Lines. Always verify the DOI, source, and publication details against the publisher record before submitting a manuscript.

Follow this research in Scollr

Follow the topics and authors behind this paper, save useful studies, and build a literature map when you are ready to go deeper.

Get the app